Doctors are encouraged by the results of a new study using a medication called Rituxan to help patients with multiple sclerosis (MS).
Multiple sclerosis is a chronic, inflammatory, demyelinating disease that affects the central nervous system. Disease onset usually occurs in young adults, is more common in women, and has a prevalence that ranges between 2 and 150 per 100,000 depending on the country or specific population. MS was first described in 1868 by Jean-Martin Charcot.
Rituxan is used to treat non-Hodgkin's lymphoma and rheumatoid arthritis.
Non-Hodgkin lymphoma describes a group of cancers arising from lymphocytes, a type of white blood cell. It is distinct from Hodgkin lymphoma in its pathologic features, epidemiology, common sites of involvement, clinical behavior, and treatment. The non-Hodgkin lymphomas are a diverse group of diseases with varying courses, treatments, and prognoses.
Scientists found that MS patients who got Rituxan had a reduced number of brain lesions and a lower chance of relapse than those taking a placebo.
The fact that Rituxan seems to improve MS symptoms imply it may share similarities to non-Hodgkins lymphoma and rheumatoid arthritis.
Russian Finance Minister Anton Siluanov announced a possible move that Russia can take in response to new US sanctions
The Central Bank of Turkey announced measures to protect the financial market of Turkey against the background of the collapse of the Turkish lira and conflict of interests with the United States of America